Company Overview - Insmed has experienced significant growth in 2025 and anticipates continued success in 2026 and beyond, contingent on upcoming data readouts [2][3] Product Development - The company’s ARIKAYCE program has been on the market for approximately 8 years, currently treating about 25,000 patients across three geographic territories, with the potential to expand to 250,000 patients pending success in the ENCORE trial [3] - Insmed has successfully launched its second product, BRINSUPRI, marking its transition to a two-product company [4]